SAN

93.96

+0.33%↑

MRK1

117.45

+0.43%↑

SHL.DE

48.86

-0.2%↓

ARGX

522

+2.03%↑

FRE

43.56

-0.91%↓

SAN

93.96

+0.33%↑

MRK1

117.45

+0.43%↑

SHL.DE

48.86

-0.2%↓

ARGX

522

+2.03%↑

FRE

43.56

-0.91%↓

SAN

93.96

+0.33%↑

MRK1

117.45

+0.43%↑

SHL.DE

48.86

-0.2%↓

ARGX

522

+2.03%↑

FRE

43.56

-0.91%↓

SAN

93.96

+0.33%↑

MRK1

117.45

+0.43%↑

SHL.DE

48.86

-0.2%↓

ARGX

522

+2.03%↑

FRE

43.56

-0.91%↓

SAN

93.96

+0.33%↑

MRK1

117.45

+0.43%↑

SHL.DE

48.86

-0.2%↓

ARGX

522

+2.03%↑

FRE

43.56

-0.91%↓

Search

Pharming Group NV

Gesloten

0.945 4.65

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.903

Max

0.952

Belangrijke statistieken

By Trading Economics

Inkomsten

4.3M

3.4M

Verkoop

18M

93M

EPS

-0.02

Winstmarge

3.657

Werknemers

404

EBITDA

1.9M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+122.26% upside

Dividenden

By Dow Jones

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

119M

609M

Vorige openingsprijs

-3.71

Vorige sluitingsprijs

0.945

Pharming Group NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mei 2025, 20:54 UTC

Acquisities, Fusies, Overnames

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mei 2025, 20:50 UTC

Winsten

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mei 2025, 23:48 UTC

Acquisities, Fusies, Overnames

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mei 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mei 2025, 23:39 UTC

Marktinformatie

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mei 2025, 23:08 UTC

Marktinformatie

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mei 2025, 22:46 UTC

Acquisities, Fusies, Overnames

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mei 2025, 22:45 UTC

Acquisities, Fusies, Overnames

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mei 2025, 22:44 UTC

Top Nieuws

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 mei 2025, 22:20 UTC

Top Nieuws

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q EPS 10c >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q Sales $972M >JHX

20 mei 2025, 20:52 UTC

Top Nieuws

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mei 2025, 20:52 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2025, 20:52 UTC

Marktinformatie

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mei 2025, 20:30 UTC

Acquisities, Fusies, Overnames

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mei 2025, 20:28 UTC

Acquisities, Fusies, Overnames

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mei 2025, 20:23 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mei 2025, 20:22 UTC

Winsten

XP 1Q Adj EPS BRL2.29 >XP

20 mei 2025, 20:22 UTC

Winsten

XP 1Q Rev BRL4.345B >XP

20 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mei 2025, 20:20 UTC

Top Nieuws

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mei 2025, 20:19 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mei 2025, 20:11 UTC

Top Nieuws

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mei 2025, 20:09 UTC

Winsten

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Peer Vergelijking

Prijswijziging

Pharming Group NV Prognose

Koersdoel

By TipRanks

122.26% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2 EUR  122.26%

Hoogste 2 EUR

Laagste 2 EUR

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pharming Group NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.